80
Participants
Start Date
June 30, 2013
Primary Completion Date
March 31, 2017
Study Completion Date
November 30, 2022
Pertuzumab + trastuzumab
"Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.~Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.~if T-DM1: 3.6 mg/kg IV, every 3 weeks."
Pertuzumab + trastuzumab + metronomic chemotherapy
Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A
UZ Antwerpen, Antwerp
Cliniques Universitaires Saint-Luc, Brussels
Institut Jules Bordet, Brussels
Hopital De Jolimont, Haine-Saint-Paul
AZ Groeninge Kortrijk, Kortrijk
UZ Leuven, Leuven
CHU Sart-Tilman, Liège
Clinique et Maternité Sainte Elisabeth, Namur
AZ Damiaan, Ostend
AZ Nikolaas, Sint-Niklaas
Centre Georges-Francois-Leclerc, Dijon
Centre Oscar Lambret, Lille
Hopital Rene Huguenin - Institut Curie, Saint-Cloud
Centre Paul Strauss, Strasbourg
Istituto Europeo Di Oncologia, Milan
Istituto Oncologico Veneto IRCCS - Ospedale Busonera, Padua
Leiden University Medical Centre, Leiden
VieCuri - Medisch Centrum voor Noord-Limburg - Locatie Venlo, Venlo
Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw
Champalimaud Cancer Center, Lisbon
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon
Sahlgrenska Universitetssjukhuet, Gothenburg
Ryhov County Hospital, Jönköping
Uppsala University Hospital - Akademiska Sjukhuset, Uppsala
Vastmanland Centralsjukhuset Vasteras, Västerås
Velindre NHS Trust - Velindre Cancer Centre, Cardiff
NHS Lothian - Western General Hospital, Edinburgh
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital, Glasgow
Peterborough and Stamford Hospitals NHS Foundation Trust - Peterborough City Hospita, Peterboroug
University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton
Hoffmann-La Roche
INDUSTRY
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK